Skip to main content
Clinical Trials/NCT05922865
NCT05922865
Completed
Not Applicable

Tri-service General Hospital, National Defence Medical Center, Taipei, Taiwan

Shang-Lin Chiang1 site in 1 country120 target enrollmentJuly 11, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronavirus Disease
Sponsor
Shang-Lin Chiang
Enrollment
120
Locations
1
Primary Endpoint
Aerobic capacity (VO2 max in ml/kg/min )
Status
Completed
Last Updated
last year

Overview

Brief Summary

The coronavirus (COVID -19) has rapidly turned into a global pandemic. For patients diagnosed with COVID-19, it caused severe damage in the upper respiratory system and systemic complications, including the cardiovascular, mental, nervous, and musculoskeletal system. Previous research has indicated that these subsequent sequelae can reduce quality of life. (A. W. Wong et al., 2020) Studies have indicated that exercise training is beneficial to improve blood pressure, reduce cardiovascular factors, reduce complications, and relieve depression (J. Galloza et al., 2017) However, the current international research on the benefits of exercise rehabilitation and the improvement of quality of life in patients who have been infected with COVID-19 is still lacking. Under the international epidemic, it is pointed out that the importance of telerehabilitation has also been advocated worldwide. Previous systematic review indicated that no matter it is nervous, muscular or cardiac system disease, the efficacy of telerehabilitation is superior to face-to-face rehabilitation. The purpose of this study is to compare the effect between the intervention of KNEESUP smart knee assistive device, and the health education in routine outpatient after diagnosis of Long Covid-19.

Detailed Description

The purpose of KNEESUP measuring equipment used in this research is to improve the recovery rate and reduce the sequelae after treatment. KNEESUP connects the subjects and researchers through technologies such as IoT and AI. The evaluation of the rehabilitation results can be presented as a data chart, and the treatment effects are also clearly presented. For the subject, the subject puts on KNEESUP knee pads in a long sitting position, bends the knees about 30 degrees, aligns the position of the knee pad circle with the bone, and uses the strap on the lower side, upper side, and the knee pads. After wearing, press and hold the sensor on the outer side of the knee pad for 3 seconds, and then open the mobile app. After the hardware setting and connection are completed, the evaluation and exercise can begin.

Registry
clinicaltrials.gov
Start Date
July 11, 2023
End Date
March 15, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Shang-Lin Chiang
Responsible Party
Sponsor Investigator
Principal Investigator

Shang-Lin Chiang

Attending physician

National Defense Medical Center, Taiwan

Eligibility Criteria

Inclusion Criteria

  • symptoms last at least one month after recovery
  • without physical impairment
  • understood verbal or non-verbal communication
  • normal cognitive function
  • were willing to participate in the study and accept random allocation

Exclusion Criteria

  • diagnosed with transient ischemic attack or stroke
  • had neuromuscular injury or surgery in the lower limbs in the past six months
  • had heart rhythm regulator
  • hospitalized during training
  • had aggravated symptoms due to infection again
  • had participated in other clinical trials or received other alternative treatments

Outcomes

Primary Outcomes

Aerobic capacity (VO2 max in ml/kg/min )

Time Frame: baseline, 12 weeks

Maximal VO2 during testing, also means aerobic capacity

Working load in watt

Time Frame: baseline, 12 weeks

Maximal Working load during testing

Rest Heart rate in beat/min

Time Frame: baseline, 12 weeks

Resting heart rate during exercise testing

O2 pulse in ml/beat

Time Frame: baseline, 12 weeks

It means the heart pumps O2 volume by each heart beat, and also means left ventricle function.

Systolic blood pressure in mm Hg

Time Frame: baseline, 12 weeks

The resting blood pressure during exercise testing

Diastolic blood pressure in mm Hg

Time Frame: baseline, 12 weeks

The resting blood pressure during exercise testing

Anaerobic Threshold (mL/kg/min)

Time Frame: baseline, 12 weeks

Anaerobic Threshold (AT) refers to the exercise intensity at which lactate begins to accumulate in the blood at a faster rate than it can be removed. It represents a transition point between predominantly aerobic metabolism (using oxygen) and increased anaerobic metabolism (without sufficient oxygen).

Breathing reserve (ml/kg/min)

Time Frame: baseline, 12 weeks

A measure used during cardiopulmonary exercise testing (CPET) to assess how much of a person's maximum ventilatory capacity is unused at peak exercise. It reflects the difference between the maximum voluntary ventilation (MVV) and the minute ventilation (VE) reached during exercise.

VE/VCO2 slope

Time Frame: baseline, 12 weeks

The ventilation/ perfusion abnormalities (VE/VCO2) is measured by graded exercise testing.The change in VE/VCO2 was calculated as the value at 12 weeks minus the value at baseline. A lower VE/VCO2 ratio indicates better ventilatory efficiency and reduced ventilation/perfusion abnormalities.

Heart rate recovery

Time Frame: baseline, 12 weeks

The heart rate recovery is measured by graded exercise testing, including 1 minute and 2 minute recovery. The change in heart rate recovery was calculated as the difference between heart rate recovery at 12 weeks and heart rate recovery at baseline. A decrease of \< 12 or 22 beats per minute in 1- or 2- min heart rate recovery, respectively, indicates an elevated risk of mortality. A faster heart rate recovery indicates better cardiovascular fitness and autonomic regulation.

FVC (L/min)

Time Frame: baseline, 12 weeks

The total amount of air exhaled (mL) during a forced expiratory volume test will be measured by spirometry. The change in FVC was calculated as the value at 12 weeks minus the value at baseline. A higher FVC indicates better lung function.

FEV1 (L/min)

Time Frame: baseline, 12 weeks

The amount of air exhaled (mL) during the first second during a forced expiratory volume test will be measured by spirometry. The change in FEV1 was calculated as the value at 12 weeks minus the value at baseline. A higher FEV1 indicates better lung function.

FEV1/FVC (%)

Time Frame: baseline, 12 weeks

The measured FEV1 is divided by the measured FVC. he change in FEV1/FVC was calculated as the value at 12 weeks minus the value at baseline. A higher FEV1/FVC ratio generally indicates better lung function, while a lower ratio suggests airflow limitation.

Gait: Step length (m) through Time Up and Go Test

Time Frame: baseline, 12 weeks

Analysis software was evaluated using METASENS. Begin by having the participants sit back in a standard arm chair and identify a 3 meters line on the floor. Participants walk forward three meters at the usual speed, turn around and return to the chair before sitting down. The METASENS evaluation analysis software calculates the step length (m), speed (m/s), cadence (steps per minute), left/right gait cycle (sec), left/right knee flexion angle (deg), left/right foot contact extension angle (deg), turn around time (sec), stand up time (sec), total walking time (sec).

Gait: Speed (m/s) through Time Up and Go Test

Time Frame: baseline, 12 weeks

Analysis software was evaluated using METASENS. Begin by having the participants sit back in a standard arm chair and identify a 3 meters line on the floor. Participants walk forward three meters at the usual speed, turn around and return to the chair before sitting down. The METASENS evaluation analysis software calculates the step length (m), speed (m/s), cadence (steps per minute), left/right gait cycle (sec), left/right knee flexion angle (deg), left/right foot contact extension angle (deg), turn around time (sec), stand up time (sec), total walking time (sec).

Gait: Cadence (steps per minute) through Time Up and Go Test

Time Frame: baseline, 12 weeks

Analysis software was evaluated using METASENS. Begin by having the participants sit back in a standard arm chair and identify a 3 meters line on the floor. Participants walk forward three meters at the usual speed, turn around and return to the chair before sitting down. The METASENS evaluation analysis software calculates the step length (m), speed (m/s), cadence (steps per minute), left/right gait cycle (sec), left/right knee flexion angle (deg), left/right foot contact extension angle (deg), turn around time (sec), stand up time (sec), total walking time (sec).

Gait: Left gait cycle (sec) through Time Up and Go Test

Time Frame: baseline, 12 weeks

Analysis software was evaluated using METASENS. Begin by having the participants sit back in a standard arm chair and identify a 3 meters line on the floor. Participants walk forward three meters at the usual speed, turn around and return to the chair before sitting down. The METASENS evaluation analysis software calculates the step length (m), speed (m/s), cadence (steps per minute), left/right gait cycle (sec), left/right knee flexion angle (deg), left/right foot contact extension angle (deg), turn around time (sec), stand up time (sec), total walking time (sec).

Gait: Right gait cycle (sec) through Time Up and Go Test

Time Frame: baseline, 12 weeks

Analysis software was evaluated using METASENS. Begin by having the participants sit back in a standard arm chair and identify a 3 meters line on the floor. Participants walk forward three meters at the usual speed, turn around and return to the chair before sitting down. The METASENS evaluation analysis software calculates the step length (m), speed (m/s), cadence (steps per minute), left/right gait cycle (sec), left/right knee flexion angle (deg), left/right foot contact extension angle (deg), turn around time (sec), stand up time (sec), total walking time (sec).

Gait: Turn around time (sec) through Time Up and Go Test

Time Frame: baseline, 12 weeks

Analysis software was evaluated using METASENS. Begin by having the participants sit back in a standard arm chair and identify a 3 meters line on the floor. Participants walk forward three meters at the usual speed, turn around and return to the chair before sitting down. The METASENS evaluation analysis software calculates the step length (m), speed (m/s), cadence (steps per minute), left/right gait cycle (sec), left/right knee flexion angle (deg), left/right foot contact extension angle (deg), turn around time (sec), stand up time (sec), total walking time (sec).

Gait: Stand up time (sec) through Time Up and Go Test

Time Frame: baseline, 12 weeks

Analysis software was evaluated using METASENS. Begin by having the participants sit back in a standard arm chair and identify a 3 meters line on the floor. Participants walk forward three meters at the usual speed, turn around and return to the chair before sitting down. The METASENS evaluation analysis software calculates the step length (m), speed (m/s), cadence (steps per minute), left/right gait cycle (sec), left/right knee flexion angle (deg), left/right foot contact extension angle (deg), turn around time (sec), stand up time (sec), total walking time (sec).

Gait: Total walking time (sec) through Time Up and Go Test

Time Frame: baseline, 12 weeks

Analysis software was evaluated using METASENS. Begin by having the participants sit back in a standard arm chair and identify a 3 meters line on the floor. Participants walk forward three meters at the usual speed, turn around and return to the chair before sitting down. The METASENS evaluation analysis software calculates the step length (m), speed (m/s), cadence (steps per minute), left/right gait cycle (sec), left/right knee flexion angle (deg), left/right foot contact extension angle (deg), turn around time (sec), stand up time (sec), total walking time (sec).

Long COVID symptoms

Time Frame: baseline, 12 weeks

A simple checklist to record Long COVID symptoms. Symptoms that persisted or were newly developed after acute infection were documented as sequelae. Symptoms included fatigue, shortness of breath, cognitive dysfunction (referred to as "brain fog"), chest pain, cough, dizziness, headache, sleep disturbances, palpitations, depression/anxiety, and olfactory dysfunction.

Secondary Outcomes

  • Quality of life (scores)(baseline, 12 weeks)
  • Sleeping Quality (scores)(baseline, 12 weeks)
  • Body composition: Body weight (kg)(baseline, 12 weeks)
  • Body composition: Body fat (%)(baseline, 12 weeks)
  • Body composition: Lean mass weight (kg)(baseline, 12 weeks)

Study Sites (1)

Loading locations...

Similar Trials